SRPT – Sarepta Therapeutics, Inc.
SRPT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
28.23
Margin Of Safety %
-24
Put/Call OI Ratio
0.72
EPS Next Q Diff
0.06
EPS Last/This Y
11.92
EPS This/Next Y
-2.34
Price
16.78
Target Price
22.09
Analyst Recom
2.73
Performance Q
-19.33
Upside
-324.7%
Beta
0.23
Ticker: SRPT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | SRPT | 18.82 | 0.93 | 0.17 | 78906 |
| 2026-07-14 | SRPT | 17.97 | 0.93 | 0.12 | 79416 |
| 2026-07-15 | SRPT | 17.61 | 0.92 | 0.24 | 79994 |
| 2026-07-16 | SRPT | 17.23 | 0.91 | 0.15 | 81169 |
| 2026-07-17 | SRPT | 17.2 | 0.90 | 0.10 | 81682 |
| 2026-07-20 | SRPT | 16.83 | 0.94 | 0.10 | 75901 |
| 2026-07-21 | SRPT | 16.2 | 0.92 | 0.17 | 77144 |
| 2026-07-22 | SRPT | 15.81 | 0.89 | 0.12 | 79502 |
| 2026-07-23 | SRPT | 15.87 | 0.88 | 0.22 | 80211 |
| 2026-07-24 | SRPT | 15.67 | 0.86 | 0.21 | 80727 |
| 2026-07-27 | SRPT | 15.89 | 0.86 | 0.21 | 79589 |
| 2026-07-28 | SRPT | 15.46 | 0.85 | 0.27 | 80827 |
| 2026-07-29 | SRPT | 15.53 | 0.84 | 0.11 | 83263 |
| 2026-07-30 | SRPT | 15.56 | 0.84 | 0.47 | 83707 |
| 2026-07-31 | SRPT | 14.85 | 0.83 | 0.28 | 84624 |
| 2026-08-03 | SRPT | 15.89 | 0.86 | 0.16 | 82726 |
| 2026-08-04 | SRPT | 16.39 | 0.80 | 0.07 | 87246 |
| 2026-08-05 | SRPT | 15.9 | 0.77 | 0.72 | 89967 |
| 2026-08-06 | SRPT | 16.77 | 0.77 | 0.21 | 93676 |
| 2026-08-07 | SRPT | 16.78 | 0.72 | 0.08 | 98949 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | SRPT | 18.83 | -75.3 | - | 4.84 |
| 2026-07-14 | SRPT | 17.95 | -75.9 | - | 4.81 |
| 2026-07-15 | SRPT | 17.60 | -75.9 | - | 4.81 |
| 2026-07-16 | SRPT | 17.24 | -75.9 | - | 4.81 |
| 2026-07-17 | SRPT | 17.20 | -75.9 | - | 4.81 |
| 2026-07-20 | SRPT | 16.83 | -75.9 | - | 4.81 |
| 2026-07-21 | SRPT | 16.21 | -75.9 | - | 4.79 |
| 2026-07-22 | SRPT | 15.81 | -75.9 | - | 4.79 |
| 2026-07-23 | SRPT | 15.87 | -75.9 | - | 4.79 |
| 2026-07-24 | SRPT | 15.66 | -75.9 | - | 4.79 |
| 2026-07-27 | SRPT | 15.89 | -75.9 | - | 4.79 |
| 2026-07-28 | SRPT | 15.45 | -75.9 | - | 4.79 |
| 2026-07-29 | SRPT | 15.53 | -75.9 | - | 4.79 |
| 2026-07-30 | SRPT | 15.56 | -75.9 | - | 4.79 |
| 2026-07-31 | SRPT | 14.85 | -75.9 | - | 4.79 |
| 2026-08-03 | SRPT | 15.88 | -75.9 | - | 4.79 |
| 2026-08-04 | SRPT | 15.88 | -75.9 | - | 4.79 |
| 2026-08-05 | SRPT | 15.92 | -75.9 | - | 4.79 |
| 2026-08-06 | SRPT | 16.79 | -75.9 | - | 4.79 |
| 2026-08-07 | SRPT | 16.78 | -75.9 | - | 4.79 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | SRPT | -0.16 | 12.00 | 28.47 |
| 2026-07-14 | SRPT | -0.16 | 12.00 | 28.47 |
| 2026-07-15 | SRPT | -0.16 | 12.00 | 28.47 |
| 2026-07-16 | SRPT | -0.16 | 12.00 | 28.47 |
| 2026-07-17 | SRPT | -0.16 | 12.00 | 28.47 |
| 2026-07-20 | SRPT | -0.16 | 12.04 | 28.47 |
| 2026-07-21 | SRPT | -0.16 | 12.04 | 28.47 |
| 2026-07-22 | SRPT | -0.16 | 12.04 | 28.47 |
| 2026-07-23 | SRPT | -0.16 | 12.04 | 28.47 |
| 2026-07-24 | SRPT | -0.16 | 12.04 | 28.47 |
| 2026-07-27 | SRPT | -0.16 | 11.92 | 28.23 |
| 2026-07-28 | SRPT | -0.16 | 11.92 | 28.23 |
| 2026-07-29 | SRPT | -0.16 | 11.92 | 28.23 |
| 2026-07-30 | SRPT | -0.16 | 11.92 | 28.23 |
| 2026-07-31 | SRPT | -0.16 | 11.92 | 28.23 |
| 2026-08-03 | SRPT | -0.16 | 12.50 | 28.23 |
| 2026-08-04 | SRPT | -0.16 | 12.50 | 28.23 |
| 2026-08-05 | SRPT | -0.16 | 12.50 | 28.23 |
| 2026-08-06 | SRPT | -0.16 | 12.50 | 28.23 |
| 2026-08-07 | SRPT | -0.16 | 12.50 | 28.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.42
Avg. EPS Est. Current Quarter
0.49
Avg. EPS Est. Next Quarter
0.48
Insider Transactions
-0.16
Institutional Transactions
12.5
Beta
0.23
Average Sales Estimate Current Quarter
365
Average Sales Estimate Next Quarter
370
Fair Value
12.82
Quality Score
50
Growth Score
33
Sentiment Score
81
Actual DrawDown %
90.3
Max Drawdown 5-Year %
-92.7
Target Price
22.09
P/E
Forward P/E
21.72
PEG
P/S
0.9
P/B
1.16
P/Free Cash Flow
27.36
EPS
-2.9
Average EPS Est. Cur. Y
4.79
EPS Next Y. (Est.)
2.45
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-13.48
Relative Volume
0.89
Return on Equity vs Sector %
-36.3
Return on Equity vs Industry %
-20.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
◆
SRPT
Healthcare
$16.78
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
51.2
Range 1M
32.1%
Sup Dist
2.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
146.9%
EPS NY
-76.9%
52W%
19.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+44.1% upside
Upside
+44.1%
Quality
50
MoS
-24%
SRPT — P/E HistoricalBiotechnology
Sarepta Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 835
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT
Latest News
—
Caricamento notizie per SRPT…
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading